The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

Zealand Pharma A/S (ZLDPF) shares ended the last trading session 8% higher at $72.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...

Zealand Pharma is on a hiring spree as it bets on the success of its experimental weight-loss treatment that last month saw Swiss healthcare group Roche swoop in to partner on the drug’s ...

Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

Zealand Pharma (ZLDPF) announces the implementation of long-term incentive programs for 2025 for Zealand Pharma’s Board of Directors, Corporate ...

Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...